Edition:
United States

Dr.Reddy's Laboratories Ltd (RDY.N)

RDY.N on New York Stock Exchange

43.71USD
21 Feb 2017
Change (% chg)

$0.24 (+0.55%)
Prev Close
$43.47
Open
$43.33
Day's High
$43.82
Day's Low
$43.33
Volume
61,606
Avg. Vol
65,085
52-wk High
$54.70
52-wk Low
$41.62

Select another date:

Tue, Feb 21 2017

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents

* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement

BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release

* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."

BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"

* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:

BRIEF-Sucampo Q3 adjusted EPS $0.28

* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance

BRIEF-Dr.Reddy's Labs exec says co has addressed all FDA requirements on warning letters

* Exec says have addressed all FDA requirements on warning letters

BRIEF-Dr.Reddy's Laboratories Sept-qtr consol profit falls 60 pct

* Co to continue to focus on launching new products in generic business

BRIEF-Dr. Reddy's Labs launches Aripiprazole tablets, USP tablets in U.S. market

* Dr. Reddy's Laboratories announces the launch of Aripiprazole tablets, USP tablets in the U.S. market Source text for Eikon: Further company coverage: (Bengaluru newsroom)

Select another date:

More From Around the Web